Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.50 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL29790882 | 1.00 | TSHR (0.68) | TSHRALDH1A1LPAR3LPAR2GGPS1 | |
| Phosphoric Acid SCHEMBL31121659 | 0.98 | TSHR (0.73) | TSHRALDH1A1LPAR3LPAR2GGPS1 | |
| Phosphoric Acid SCHEMBL3093706 | 0.98 | TSHR (0.73) | TSHRALDH1A1LPAR3LPAR2GGPS1 | |
| Phosphoric Acid SCHEMBL31121657 | 0.98 | TSHR (0.73) | TSHRALDH1A1LPAR3LPAR2GGPS1 | |
| Phosphoric Acid SCHEMBL31121661 | 0.98 | TSHR (0.73) | TSHRALDH1A1LPAR3LPAR2GGPS1 | |
| Phosphoric Acid SCHEMBL3096896 | 0.98 | TSHR (0.73) | TSHRALDH1A1LPAR3LPAR2GGPS1 | |
| Phosphoric Acid SCHEMBL6862940 | 0.98 | TSHR (0.73) | TSHRALDH1A1LPAR3LPAR2GGPS1 | |
| Phosphoric Acid SCHEMBL31121662 | 0.98 | TSHR (0.73) | TSHRALDH1A1LPAR3LPAR2GGPS1 | |
| Phosphoric Acid SCHEMBL31121660 | 0.98 | TSHR (0.73) | TSHRALDH1A1LPAR3LPAR2GGPS1 | |
| Phosphoric Acid SCHEMBL28999756 | 0.98 | TSHR (0.73) | TSHRALDH1A1LPAR3LPAR2GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150132797-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | LIFE TECHNOLOGIES CORP (US) | 2015-05-14 | — | — | US | claimed |
| US-20100285601-A1 | METHOD OF ELECTRICALLY DETECTING A NUCLEIC ACID MOLECULE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-11-11 | — | — | US | claimed |
| WO-2009041917-A1 | METHOD OF ELECTRICALLY DETECTING A NUCLEIC ACID MOLECULE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-04-02 | — | — | WO | claimed |
| US-20080038772-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | INVITROGEN CORPORATION (US) | 2008-02-14 | — | — | US | claimed |
| US-20080038773-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | INVITROGEN CORPORATION (US) | 2008-02-14 | — | — | US | claimed |
| US-12296304-B2 | Membrane for water filtration | AQUAPORIN A/S (DK) | 2025-05-13 | — | — | US | disclosed |
| EP-4277731-B1 | PROCESS FOR PREPARING A MEMBRANE | AQUAPORIN AS (DK) | 2024-10-09 | — | — | EP | disclosed |
| US-20240058768-A1 | MEMBRANE FOR WATER FILTRATION | AQUAPORIN A/S (DK) | 2024-02-22 | — | — | US | disclosed |
| EP-4277731-A1 | MEMBRANE FOR WATER FILTRATION | Aquaporin A/S (DK) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022152748-A1 | MEMBRANE FOR WATER FILTRATION | AQUAPORIN A/S (DK) | 2022-07-21 | — | — | WO | disclosed |
| US-20150132797-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | LIFE TECHNOLOGIES CORP (US) | 2015-05-14 | — | — | US | disclosed |
| US-20100285601-A1 | METHOD OF ELECTRICALLY DETECTING A NUCLEIC ACID MOLECULE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-11-11 | — | — | US | disclosed |
| US-20060029568-A1 | Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents | GENZYME CORPORATION (US) | 2006-02-09 | — | — | US | disclosed |
| US-6890523-B2 | Anionic polymers as toxin binders and antibacterial agents | GENZYME CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-20030138397-A1 | Anionic polymers as toxin binders and antibacterial agents | GELTEX PHARMACEUTICALS, INC. | 2003-07-24 | — | — | US | disclosed |
| US-6517827-B1 | Polystyrene sulfonate polymer; Clostridium difficile | GELTEX PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| US-6517826-B1 | Polystyrene sulfonate polymer; Clostridium difficile | GELTEX PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-1189622-A2 | ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS | Geltex Pharmaceuticals, Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6290946-B1 | ADMINISTERING TO THE ANIMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A POLYMER HAVING A PLURALITY OF PENDANT ACID FUNCTIONAL GROUPS WHICH ARE DIRECTLY ATTACHED TO THE POLYMER BACKBONE OR ATTACHED TO THE POLYMER BACKBONE BY A SPACER GROUP. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000069428-A2 | ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060029568-A1 | Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents | DDOST, DNPEP, IDUA | TSHR 821/4885ALDH1A1 1727/4885LPAR3 907/4885 |
| US-20030138397-A1 | Anionic polymers as toxin binders and antibacterial agents | MSN, ANTXR2, PNKP | TSHR 1345/4885ALDH1A1 4470/4885LPAR3 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.